or Try an Advanced Search...

    Type II Diabetes Stocks List

    Symbol Grade Name % Change
    NMRD F Nemaura Medical Inc. -10.85
    ALKS F Alkermes plc -2.16
    NBIX A Neurocrine Biosciences, Inc. 3.99
    View As Page of Charts
    Related Industries: Biotechnology Medical Devices
    Related Stock Lists: Diabetes Type I Diabetes Alcohol Pain Schizophrenia Angina Atypical Antipsychotics Biopharmaceutical Blood Glucose Monitoring Blood Sugar Level Blood Test Cachexia Cardiovascular Disease Chemotherapy Cholesterol Clinical Development Cocaine Constipation Continuous Glucose Monitor Depressive Disorder

    Related ETFs - A few ETFs which own one or more of the above listed Type II Diabetes stocks.

    Symbol Grade Name Weight
    IBRN C iShares Neuroscience and Healthcare ETF 8.9
    FBT D First Trust Amex Biotech Index Fund 6.82
    PBE C PowerShares Dynamic Biotech & Genome 5.53
    PSIL D AdvisorShares Psychedelics ETF 4.75
    MNTL F Tema Neuroscience and Mental Health ETF 4.27
    View all Type II Diabetes ETFs...
    Compare ETFs
    Compare FBT to PSIL Compare IBRN to MNTL Compare IBRN to PSIL

        Type II Diabetes Stocks Recent News

        Date Stock Title
        May 1 NBIX Neurocrine Q1 revenue beats Street, gets FDA okay for Ingrezza Sprinkle
        May 1 NBIX Neurocrine Biosciences, Inc. (NBIX) Q1 2024 Earnings Call Transcript
        May 1 NBIX Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech
        May 1 ALKS Alkermes plc (ALKS) Q1 2024 Earnings Call Transcript
        May 1 ALKS Alkermes plc 2024 Q1 - Results - Earnings Call Presentation
        May 1 ALKS Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say
        May 1 NBIX Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
        May 1 ALKS Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
        May 1 NBIX Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
        May 1 NBIX Neurocrine Biosciences Non-GAAP EPS of $1.20 misses by $0.09, revenue of $515.3M beats by $3.29M
        May 1 ALKS Alkermes Non-GAAP EPS of $0.43 misses by $0.15, revenue of $350.4M misses by $9.87M
        May 1 NBIX Neurocrine Biosciences Reports First Quarter 2024 Financial Results
        May 1 ALKS Alkermes plc Reports First Quarter 2024 Financial Results
        Apr 30 NBIX UPDATE 2-Neurocrine Biosciences' Huntington's disease drug gets FDA approval
        Apr 30 NBIX Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
        Apr 30 ALKS Alkermes Q1 2024 Earnings Preview
        Apr 30 NBIX Neurocrine Biosciences Q1 2024 Earnings Preview
        Apr 30 NBIX Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics
        Apr 30 ALKS How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits?
        Apr 25 NBIX Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
        Related Industries: Biotechnology Medical Devices
        Related Stock Lists: Diabetes Type I Diabetes Alcohol Pain Schizophrenia Angina Atypical Antipsychotics Biopharmaceutical Blood Glucose Monitoring Blood Sugar Level Blood Test Cachexia Cardiovascular Disease Chemotherapy Cholesterol Clinical Development Cocaine Constipation Continuous Glucose Monitor Depressive Disorder
        Type II Diabetes

        Type 2 diabetes is a chronic condition that affects the way the body processes blood sugar (glucose). It is the most common form of diabetes, and it occurs when the body does not produce enough insulin or does not use insulin properly. People with type 2 diabetes may need to take medication or make lifestyle changes to manage their condition.

        Browse All Tags